Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O95274

UPID:
LYPD3_HUMAN

ALTERNATIVE NAMES:
GPI-anchored metastasis-associated protein C4.4A homolog; Matrigel-induced gene C4 protein

ALTERNATIVE UPACC:
O95274; Q9UJ74

BACKGROUND:
The protein Ly6/PLAUR domain-containing protein 3, with alternative names GPI-anchored metastasis-associated protein C4.4A homolog and Matrigel-induced gene C4 protein, supports cell migration and may be crucial for urothelial cell-matrix interactions. Its potential involvement in tumor progression positions it as a key player in cancer research.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ly6/PLAUR domain-containing protein 3 offers a pathway to innovative therapeutic approaches. Given its role in cell migration and possible contribution to tumor progression, targeting this protein could lead to breakthroughs in cancer therapy.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.